Stefan Ryser

Chief Executive Officer at

Trellis Bioscience, Inc.

66 year

61 connections

Health Technology

Finance

Commercial Services

Profile

Stefan Ryser was the founder of International Biomedicine Management Partners AG, founded in 1998, holding the title of Chief Executive Officer in 2000.
Dr. Ryser is the founder of Bear Stearns Health Innoventures Management LLC, with the title of Founding Partner from 2000 to 2009.
Current job includes President, Chief Executive Officer & Director at Trellis Bioscience, Inc. since 2013.
Former jobs include Chief Executive Officer & Director at A-CUBE, Inc., Director at Arena Pharmaceuticals, Inc., Director at Achillion Pharmaceuticals, Inc., Managing Director at Bear Stearns Asset Management, Inc., Director at Entelos, Inc., Director at Tolerx, Inc., Director at Genaissance Pharmaceuticals, Inc., Director at Cytokinetics, Inc., Director & Senior VP-Corporate Strategy at Telik, Inc. from 1998 to 2009, and Head-Research Staff at Hoffmann-La Roche, Inc. from 1989 to 1997.
Education includes undergraduate and doctorate degrees from the University of Basel.

Stefan Ryser active positions

Companies	Position	Start
Trellis Bioscience, Inc. Trellis Bioscience, Inc. BiotechnologyHealth Technology Develops treatments for infectious diseases, cancer and oncology indications	Chief Executive Officer	2012-12-31

All active positions of Stefan Ryser

Former positions of Stefan Ryser

Companies	Position	End
Telik, Inc. Telik, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and commercializing novel small molecule drugs to treat serious diseases	Director/Board Member	2009-07-31
Bear Stearns Health Innoventures Management LLC Bear Stearns Health Innoventures Management LLC Investment ManagersFinance BSHI seeks to invest in private companies with innovative research & development in areas of biotechnology. The firm prefers to be the lead investor in companies with the following characteristics: consistency with vision based on potential to enhance productivity, quality and cost-effectiveness of health care, market segment at an inflection point, innovative product or service and a proprietary, defensible and sustainable technology platform. They also look for management excellence, manageable regulatory risks and a viable business model based on market size, demand/medical need, sustainable margins, suitability for alliances and technology-into-product feasibility.	Chief Investment Officer	2009-03-30
ACHILLION PHARMACEUTICALS, INC.	Director/Board Member	2007-04-26
International Biomedicine Management Partners AG International Biomedicine Management Partners AG Investment ManagersFinance Acts as an alternative investment manager	Founder	2000-03-31
Hoffmann-La Roche, Inc. Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions	Corporate Officer/Principal	1997-12-30

See the detail of Stefan Ryser's experience

Training of Stefan Ryser

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Stefan Ryser's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	16
Roche Holding AG Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics	Health Technology
Bear Stearns Asset Management, Inc. Bear Stearns Asset Management, Inc. Investment ManagersFinance Bear Stearns Asset Management, Inc. is an asset management firm and broker/dealer located in New York City. The firm is a subsidiary of JPMorgan Asset Management, Inc. and their ultimate parent is JPMorgan Chase & Co., Inc. (NYSE: JPM). They manage equity and fixed-income separate accounts, mutual funds, hedge funds, private equity funds and venture capital funds. Their clients include corporations, municipal governments, multi-employer plans, endowments, foundations, family groups and high net-worth individuals	Finance
Telik, Inc. Telik, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and commercializing novel small molecule drugs to treat serious diseases	Health Technology
Genaissance Pharmaceuticals, Inc. Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and uses genetic information to diagnostic and therapeutic products	Health Technology
Arena Pharmaceuticals, Inc. Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products	Health Technology
Tolerx, Inc. Tolerx, Inc. BiotechnologyHealth Technology Manufactures biopharmaceutical products	Health Technology
Cytokinetics, Inc. Cytokinetics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes novel drug products	Health Technology
Trellis Bioscience, Inc. Trellis Bioscience, Inc. BiotechnologyHealth Technology Develops treatments for infectious diseases, cancer and oncology indications	Health Technology
Achillion Pharmaceuticals, Inc. Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases	Health Technology
Entelos, Inc. Entelos, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical trial partner that supports drug research and development teams	Commercial Services
Hoffmann-La Roche, Inc. Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions	Health Technology
Bear Stearns Health Innoventures Management LLC Bear Stearns Health Innoventures Management LLC Investment ManagersFinance BSHI seeks to invest in private companies with innovative research & development in areas of biotechnology. The firm prefers to be the lead investor in companies with the following characteristics: consistency with vision based on potential to enhance productivity, quality and cost-effectiveness of health care, market segment at an inflection point, innovative product or service and a proprietary, defensible and sustainable technology platform. They also look for management excellence, manageable regulatory risks and a viable business model based on market size, demand/medical need, sustainable margins, suitability for alliances and technology-into-product feasibility.	Finance
University of Basel University of Basel Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
International Biomedicine Management Partners AG International Biomedicine Management Partners AG Investment ManagersFinance Acts as an alternative investment manager	Finance
The European Association for Bioindustries
A-CUBE, Inc. A-CUBE, Inc. BiotechnologyHealth Technology Develops novel antibodies	Health Technology